# Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

> **NCT07234019** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 160 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** Daratumumab（Anti-CD38 Monoclonal Antibody）
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT07234019
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234019, "Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07234019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*